Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 15/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366736 | 0.75 | HPGDS (0.44) | HPGDSDRD2DRD4 | |
| SCHEMBL1364946 | 0.75 | DRD4 (0.43) | HPGDSGRM5DRD2DRD4 | |
| SCHEMBL1367373 | 0.74 | HPGDS (0.41) | HPGDSGRM5DRD2DRD4HTR7 | |
| SCHEMBL1364881 | 0.74 | HPGDS (0.41) | HPGDSDRD2HTR7 | |
| SCHEMBL1366908 | 0.73 | HPGDS (0.41) | HPGDSDRD2DRD4 | |
| SCHEMBL1366021 | 0.70 | DRD2 (0.52) | HPGDSGRM5DRD2DRD4HTR7 | |
| SCHEMBL10252034 | 0.70 | GABRA5 (0.58) | HPGDSGRM5 | |
| SCHEMBL1365098 | 0.70 | HPGDS (0.52) | HPGDSGRM5DRD2HTR7 | |
| SCHEMBL1368210 | 0.70 | HPGDS (0.55) | HPGDSGRM5DRD2DRD4HTR7 | |
| SCHEMBL1365691 | 0.69 | MAP4K4 (0.59) | HPGDSGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885TAS1R3 4260/4885TAS1R1 3940/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885TAS1R3 4260/4885TAS1R1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.